Management of acute severe ulcerative colitis

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 4, 2009, Pages 395-405

  Doherty, Glen A ^a   Cheifetz, Adam S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Ciclosporin; Colectomy; Corticosteroid; Infliximab; Management; Ulcerative colitis

Indexed keywords

BASILIXIMAB; BETA INTERFERON; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; INFLIXIMAB; METHYLPREDNISOLONE; MLN 02; PANITUMUMAB; PHOSPHATIDYLCHOLINE; PLACEBO; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ANTIBODY; VISILIZUMAB;

ACUTE DISEASE; ANAPHYLAXIS; CLINICAL TRIAL; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DEMYELINATING DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; FECES INCONTINENCE; GINGIVA HYPERPLASIA; HAIR LOSS; HUMAN; HYPERTENSION; HYPERTRICHOSIS; ILEITIS; ILEOSTOMY; INFECTION; LIVER FUNCTION TEST; LIVER INJURY; LOW DRUG DOSE; LYMPHOMA; MONOTHERAPY; NAUSEA AND VOMITING; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PARESTHESIA; PROCTOCOLECTOMY; QUALITY OF LIFE; REVIEW; SEIZURE; SIDE EFFECT; TREMOR; ULCERATIVE COLITIS;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CLINICAL PROTOCOLS; COLITIS, ULCERATIVE; COLONIC POUCHES; CYCLOSPORINE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DRUG RESISTANCE; GASTROINTESTINAL AGENTS; HUMANS; PATIENT SELECTION; PROCTOCOLECTOMY, RESTORATIVE; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70049087735     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.24     Document Type: Review

References (89)

1. Solberg IC, Lygren I, Jahnsen J et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand. J. Gastroenterol. 44(4), 431-440 (2008).
2. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig. Dis. Sci. 38(6), 1137-1146 (1993).
3. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J. 2(4947), 1041-1048 (1955).
4. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 99(7), 1371-1385 (2004).
5. Travis SPL, Stange EF, Lémann M et al. European evidence-based consensus on the management of ulcerative colitis: current management. J. Crohn's Colitis (2), 24-62 (2008).
6. Jess T, Riis L, Vind I et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm. Bowel Dis. 13(4), 481-489 (2007).
7. Stephen ER, Williams JG, Yeates D, Goldacre MJ. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. Br. Med. J. 335(7628), 1033 (2007).
8. Sonnenberg A. Time trends of mortality from Crohn's disease and ulcerative colitis. Int. J. Epidemiol. 36(4), 890-899 (2007).
9. Brown SR, Haboubi N, Hampton J, George B, Travis SP. The management of acute severe colitis: ACPGBI position statement. Colorectal. Dis. 10(Suppl. 3), 8-29 (2008).
10. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 53(Suppl. 5), V1-V16 (2004).
11. Maher MM, Nassar MI. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig. Dis. Sci. DOI: 10.1007/s10620-008-0639-6 (2008).
12. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am. J. Gastroenterol. 103(6), 1443-1450 (2008).
13. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin. Gastroenterol. Hepatol. 5(1), 103-110 (2007).
14. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1(7866), 1067-1070 (1974).
15. Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J. Clin. Gastroenterol. 12(1), 40-41 (1990).
16. Mantzaris GJ, Petraki K, Archavlis E et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand. J. Gastroenterol. 36(9), 971-974 (2001).
17. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 27(10), 1210-1212 (1986).
18. Dickinson RJ, Ashton MG, Axon AT, Smith RC, Yeung CK, Hill GL. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 79(6), 1199-1204 (1980).
19. McIntyre PB, Powell-Tuck J, Wood SR et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut. 27(5), 481-485 (1986).
20. Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC. Assessment of severity in colitis: a preliminary study. Gut 16(8), 579-584 (1975).
21. Travis SP. Predicting outcome in severe ulcerative colitis. Gut 38(6), 905-910 (1996).
22. Westwood N, Travis SP. Review article: what do patients with inflammatory bowel disease want for their clinical management? Aliment. Pharmacol. Ther. 27(Suppl. 1), 1-8 (2008).
23. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330(26), 1841-1845 (1994).
24. Garcia-Lopez S, Gomollon-Garcia F, Perez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol. Hepatol. 28(10), 607-614 (2005).
25. Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment. Pharmacol. Ther. 22(10), 907-916 (2005).
26. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst. Rev. (1), CD004277 (2005).
27. D'Haens G, Lemmens L, Geboes K et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120(6), 1323-1329 (2001).
28. Sternthal MB, Murphy SJ, George J et al. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am. J. Gastroenterol. 103(4), 937-943 (2008).
29. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur. J. Gastroenterol. Hepatol. 17(1), 79-84 (2005).
30. Cullen G, Keegan D, O'Donoghue D. Safety and efficacy of cyclosporine therapy in inflammatory bowel disease. Am. J. Gastroenterol. 103(10), 2654-2655 (2008).
31. Arts J, D'Haens G, Zeegers M et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm. Bowel Dis. 10(2), 73-78 (2004).
32. Moskovitz DN, Van Assche G, Maenhout B et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 4(6), 760-765 (2006).
33. Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user's guide. Am. J. Gastroenterol. 92(9), 1424-1428 (1997).
34. Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm. Bowel Dis. 4(4), 276-279 (1998).
35. Navazo L, Salata H, Morales S et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand. J. Gastroenterol. 36(6), 610-614 (2001).
36. Weber A, Fein F, Koch S et al. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm. Bowel Dis. 12(12), 1131-1135 (2006).
37. Haslam N, Hearing SD, Probert CS. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects. Eur. J. Gastroenterol. Hepatol. 12(6), 657-660 (2000).
38. Hyde GM, Jewell DP, Kettlewell MGW, Mortensen NJ. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis. Colon Rectum 44(10), 1436-1440 (2001).
39. Poritz LS, Rowe WA, Swenson BR, Hollenbeak CS, Koltun WA. Intravenous cyclosporine for the treatment of severe steroid-refractory ulcerative colitis: what is the cost? Dis. Colon Rectum 48(9), 1685-1690 (2005).
40. Domènech E, Garcia-Planella E, Bernal I et al. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment. Pharmacol. Ther. 16(12), 2061-2065 (2002).
41. Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol. 7, 13 (2007).
42. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am. J. Gastroenterol. 94(6), 1587-1592 (1999).
43. Ogata H, Matsui T, Nakamura M et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55(9), 1255-1262 (2006).
44. Fellermann K, Tanko Z, Herrlinger KR et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm. Bowel Dis. 8(5), 317-324 (2002).
45. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm. Bowel Dis. 5(1), 1-10 (1999).
46. Rutgeers P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005).
47. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment. Pharmacol. Ther. 25(1), 19-37 (2007).
48. Sands BE, Tremaine WJ, Sandborn WJ et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis. 7(2), 83-88 (2001).
49. Probert CS, Hearing SD, Schreiber S et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52(7), 998-1002 (2003).
50. Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128(7), 1805-1811 (2005).
51. Lees CW, Heys D, Ho GT et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment. Pharmacol. Ther. 26(3), 411-419 (2007).
52. Aratari A, Papi C, Clemente V et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig. Liver Dis. 40(10), 821-826 (2008).
53. Gusttavsson A, Jarnerot G, Hertervig E. A 2-year follow up study of the Swedish - Danish infliximab trial in steroid resistant acute ulcerative colitis Gastroenterology 132(4 Suppl. 2), 983-984 (2007).
54. Kohn A, Daperno M, Armuzzi A et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment. Pharmacol. Ther. 26(5), 747-756 (2007).
55. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment. Pharmacol. Ther. 25(9), 1055-1060 (2007).
56. Colombel JF, Loftus EV, Tremaine WJ et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am. J. Gastroenterol. 99(5), 878-883 (2004).
57. Marchal L, D'Haens G, Van Assche G et al. The risk of postoperative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment. Pharmacol. Ther. 19(7), 749-754 (2004).
58. Appau KA, Fazio VW, Shen B et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J. Gastrointest. Surg. 12(10), 1738-1744 (2008).
59. Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J. Gastrointest. Surg. 12(10), 1730-1737 (2008).
60. Schluender SJ, Ippoliti A, Dubinsky M et al. Does infliximab influence surgical morbidity of ileal pouch - anal anastomosis in patients with ulcerative colitis? Dis. Colon Rectum. 50(11), 1747-1753 (2007).
61. Selvasekar CR, Cima RR, Larson DW et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J. Am. Coll. Surg. 204(5), 956-963 (2007).
62. Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J. Clin. Gastroenterol. 40(8), 669-677 (2006).
63. Bermejo F, López-Sanroman A, Hinojosa J, Castro L, Jurado C, Gómez-Beldal AB. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev. Esp. Enferm. Dig. 96(2), 94-101 (2004).
64. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann. Pharmacother. 35(7-8), 823-828 (2001).
65. Mamula P, Markowitz JE, Brown KA, Hurd LB, Piccoli DA, Baldassano RN. Infliximab as a novel therapy for pediatric ulcerative colitis. J. Pediatr. Gastroenterol. Nut. 34(3), 307-311 (2002).
66. Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J. Pediatr. Gastroenterol. Nutr. 38(3), 298-301 (2004).
67. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin. Gastroenterol. Hepatol. 6(10), 1112-1116 (2008).
68. Teeuwen PH, Stommel MW, Bremers AJ, van der Wilt GJ, de Jong DJ, Bleichrodt RP. Colectomy in patients with acute colitis: a systematic review. J. Gastrointest. Surg. 13(4), 676-686 (2009).
69. Marceau C, Alves A, Ouaissi M, Bouhnik Y, Valleur P, Panis Y. Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. Surgery 141(5), 640-644 (2007).
70. Boller AM, Larson DW. Laparoscopic restorative proctocolectomy for ulcerative colitis. J. Gastrointest. Surg. 11(1), 3-7 (2007).
71. Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch - anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br. J. Surg. 85(6), 800-803 (1998).
72. Hueting WE, Buskens E, van der Tweel I, Gooszen HG, van Laarhoven CJ. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. Dig. Surg. 22(1-2), 69-79 (2005).
73. Pemberton JH, Kelly KA, Beart RW, Dozois RR, Wolff BG, Ilstrup DM. Ileal pouch - anal anastomosis for chronic ulcerative colitis. Long-term results. Ann. Surg. 206(4), 504-513 (1987).
74. Hahnloser D, Pemberton JH, Wolff BG, Larson DR, Crownhart BS, Dozois RR. Results at up to 20 years after ileal pouch - anal anastomosis for chronic ulcerative colitis. Br. J. Surg. 94(3), 333-340 (2007).
75. Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology 124(6), 1636-1650 (2003).
76. Shen B, Remzi FH, Lavery IC, Lashner BA, Fazio VW. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin. Gastroenterol. Hepatol. 6(2), 145-158 (2008).
77. Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 55(11), 1575-1580 (2006).
78. Davies RJ, O'Connor BI, Victor C, MacRae HM, Cohen Z, McLeod RS. A prospective evaluation of sexual function and quality of life after ileal pouch - anal anastomosis. Dis. Colon Rectum 51(7), 1032-1035 (2008).
79. Creed TJ, Norman MR, Probert CS et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment. Pharmacol. Ther. 18(1), 65-75 (2003).
80. Creed TJ, Probert CS, Norman MN et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment. Pharmacol. Ther. 23(10), 1435-1442 (2006).
81. Plevy S, Salzberg B, Van Assche G et al. A Phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133(5), 1414-1422 (2007).
82. 7 integrin. N. Engl. J. Med. 352(24), 2499-2507 (2005).
83. Barta Z, Toth L, Zeher M. Pulse cyclodophosphamide therapy for inflammatory bowel disease. World J. Gastroenterol. 12(8), 1278-1280 (2006).
84. Aoki H, Nakamura K, Yoshimatsu Y et al. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig. Dis. Sci. 52(6), 1427-1433 (2007).
85. Lazzerini M, Martelossi S, Marchetti F et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment. Pharmacol. Ther. 25(4), 419-427 (2007).
86. Musch E, Andus T, Malek M, Chrissafidou A, Schulz M. Successful treatment of steroid-refractory active ulcerative colitis with natural interferon-β - an open long-term trial. Z. Gastroenterol. 45(12), 1235-1240 (2007).
87. Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-β in patients with steroid-refractory active ulcerative colitis - an open long-term pilot trial. Aliment. Pharmacol. Ther. 16(7), 1233-1239 (2002).
88. Stremmel W, Ehehalt R, Autschbach F, Karner M. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann. Intern. Med. 147(9), 603-610 (2007).
89. Arseneau KO, Sultan S, Provenzale DT et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin. Gastroenterol. Hepatol. 4(9), 1135-1142 (2006).